Opportunity Information: Apply for PAR 25 050
This NIH funding opportunity (PAR 25-050) supports projects that take a promising biomarker for a neurological or neuromuscular disorder and do the hard, method-focused work needed to prove the biomarker can be measured reliably enough for real-world use. The emphasis is on analytical validation of the measurement method(s), meaning applicants are expected to rigorously test and document how well the assay or detection approach performs, so the resulting biomarker readout can be trusted in clinical trials and, potentially, in clinical practice. The award mechanism is a U01 cooperative agreement, which typically means NIH staff will have substantial scientific involvement during the project, and the NOFO is labeled "Clinical Trial Optional," so a clinical trial is not required but may be proposed if it fits the validation goals.
A central expectation is that applicants clearly explain why the biomarker is needed and what problem it solves. That includes describing the unmet need in the disease area, why existing biomarkers or tools are inadequate, and why the proposed measurement method is the right approach. Applicants must also define one or two specific "contexts of use" for the biomarker. In practical terms, this means stating exactly how the biomarker will be used (for example, patient selection, prognosis, pharmacodynamic response, disease monitoring, or another clearly articulated use case) and in what setting (clinical trial decision-making, routine clinical care, or another specified scenario). The NOFO is not asking for general biomarker discovery; it is asking for a focused plan that ties a specific biomarker measurement method to a defined use case and then demonstrates that the method performs to a standard appropriate for that use.
The work supported under this announcement includes optimizing the assay and then evaluating key analytical performance characteristics. That includes accuracy and precision (how close measurements are to the true value and how consistent they are), the reportable range (the range over which the assay can produce reliable quantitative results), and analytical sensitivity and specificity (how well the method detects the biomarker when it is present and avoids false detection when it is not, in the analytical sense). The NOFO also calls for evaluation across multiple sites and operators, highlighting a goal of showing that results are reproducible beyond a single lab or a single highly specialized technician. Multi-site applications are expected but not strictly required, so an applicant can propose a single-site plan if it is well justified, but the overall intent is to produce evidence that the method can perform robustly under conditions similar to those seen in multicenter trials or broader clinical deployment.
Beyond performance testing, applicants are expected to establish practical infrastructure for dependable measurement. This includes developing reference intervals (benchmarks for interpreting results, such as what is considered typical across relevant populations) and putting quality control procedures in place. In effect, the NOFO is aimed at moving a biomarker method from "promising but variable" to "standardized and defensible," where sample handling, instrument calibration, operator training, and ongoing QC are defined clearly enough that other groups can reproduce the results and regulators, trial sponsors, and clinicians can have confidence in the readouts.
The opportunity is offered by the National Institutes of Health under CFDA 93.853 in the health funding category. The application due date listed is June 22, 2026. Eligibility is broad and includes many types of U.S.-based organizations and governments: state, county, and city governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses) as well as small businesses; and other eligible entities. The NOFO also explicitly highlights a range of institution types as other eligible applicants, including HBCUs, Hispanic-serving institutions, Tribal Colleges and Universities, AANAPISI institutions, Alaska Native and Native Hawaiian serving institutions, faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
Foreign organizations are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible to apply. However, foreign components are allowed as defined by the NIH Grants Policy Statement, meaning a U.S. applicant organization may include certain foreign elements in the project when they are justified and structured according to NIH policy, even though a non-U.S. organization cannot be the applicant.
Overall, the NOFO is best read as a bridge-building program for biomarkers in neurology and neuromuscular disease: it funds the analytical groundwork needed to standardize and prove an assay so that a biomarker can be used confidently for a specific purpose in trials or practice, with a strong preference for demonstrating reproducibility across people and places, and for producing the reference ranges and quality systems that make the method deployable rather than merely publishable.Apply for PAR 25 050
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853.
- This funding opportunity was created on 2024-10-02.
- Applicants must submit their applications by 2026-06-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH PAR 25-050 (Analytical Validation of Neurological/Neuromuscular Biomarkers)
1) What is PAR 25-050 funding?
PAR 25-050 is an NIH funding opportunity that supports projects focused on analytical validation of a promising biomarker for a neurological or neuromuscular disorder. The goal is to do the method-focused work needed to show the biomarker can be measured reliably enough for real-world use, especially for clinical trials and potentially clinical practice.
2) What is the main goal of this opportunity?
The main goal is to generate rigorous evidence that a specific biomarker measurement method (assay or detection approach) performs in a way that is standardized, reproducible, and defensible. This includes demonstrating performance characteristics and building the practical infrastructure (reference intervals and quality control) needed so others can trust and reproduce the biomarker readout.
3) Does this opportunity support biomarker discovery?
No. The announcement is not asking for general biomarker discovery. It is aimed at taking a promising biomarker and validating the measurement method for a clearly defined use, rather than identifying new biomarkers.
4) What does "analytical validation" mean in this NOFO?
In this context, analytical validation means rigorously testing and documenting how well the biomarker measurement method performs. The expectation is to show that the assay/detection approach produces results that can be trusted, including consistency and reproducibility across different operators and (ideally) sites.
5) What kinds of projects are a good fit for PAR 25-050?
Projects are a good fit when they focus on optimizing a biomarker assay and then evaluating core analytical performance characteristics (such as accuracy, precision, reportable range, sensitivity, and specificity), along with establishing reference intervals and quality control procedures so the method can be deployed reliably beyond a single laboratory.
6) What are applicants expected to explain about the biomarker's importance?
Applicants are expected to clearly explain why the biomarker is needed and what problem it solves. This includes describing the unmet need in the disease area, why existing biomarkers/tools are inadequate, and why the proposed measurement method is the right approach.
7) What is a "context of use," and how many are required?
A context of use is a specific statement of exactly how the biomarker will be used and in what setting. Applicants must define one or two contexts of use. Examples mentioned include patient selection, prognosis, pharmacodynamic response, disease monitoring, or another clearly articulated use case, in settings such as clinical trial decision-making or routine clinical care.
8) What performance characteristics should be evaluated?
The NOFO calls for evaluating key analytical performance characteristics, including:
- Accuracy (closeness to the true value)
- Precision (consistency/repeatability of measurements)
- Reportable range (range over which reliable quantitative results can be produced)
- Analytical sensitivity (ability to detect the biomarker when present, in the analytical sense)
- Analytical specificity (ability to avoid false detection when the biomarker is not present, in the analytical sense)
9) Is assay optimization included in the scope?
Yes. The supported work includes optimizing the assay and then evaluating the analytical performance characteristics needed to show the method is reliable for its intended context of use.
10) Are multi-site studies required?
Multi-site applications are expected but not strictly required. An applicant may propose a single-site plan if it is well justified. However, the overall intent is to demonstrate that results are reproducible beyond a single lab or a single highly specialized technician.
11) Why does the NOFO emphasize multiple sites and operators?
The emphasis reflects a goal of demonstrating reproducibility under conditions similar to multicenter clinical trials or broader clinical deployment, where different sites, instruments, and operators may be involved.
12) What practical infrastructure does the NOFO expect applicants to establish?
Beyond performance testing, applicants are expected to establish infrastructure for dependable measurement, including:
- Reference intervals (benchmarks for interpreting results across relevant populations)
- Quality control procedures (processes to support ongoing reliability of measurements)
The intent is to move a biomarker method from variable to standardized, with defined sample handling, calibration, operator training, and QC.
13) What is the award mechanism for this funding opportunity?
The award mechanism is a U01 cooperative agreement, which typically means NIH staff will have substantial scientific involvement during the project.
14) Are clinical trials required under PAR 25-050?
No. The NOFO is labeled "Clinical Trial Optional", meaning a clinical trial is not required. A clinical trial may be proposed if it fits the analytical validation goals.
15) What disease areas are targeted?
The funding opportunity targets biomarkers for neurological or neuromuscular disorders.
16) When is the application due?
The application due date listed is June 22, 2026.
17) What is the CFDA number and funding category?
The opportunity is offered by NIH under CFDA 93.853 in the health funding category.
18) Who is eligible to apply?
Eligibility is broad for U.S.-based organizations and governments, including (as described):
- State, county, and city governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments and other tribal organizations
- Public housing authorities/Indian housing authorities
- Nonprofits with or without 501(c)(3) status
- For-profit organizations (other than small businesses) and small businesses
- Other eligible entities
19) Are specific institution types explicitly highlighted as eligible?
Yes. The NOFO explicitly highlights a range of institution types as other eligible applicants, including HBCUs, Hispanic-serving institutions, Tribal Colleges and Universities, AANAPISI institutions, Alaska Native and Native Hawaiian serving institutions, faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
20) Are foreign organizations eligible to apply as the applicant?
No. Foreign organizations are not eligible to apply.
21) Are non-U.S. components of U.S. organizations eligible?
No. Non-U.S. components of U.S. organizations are not eligible to apply.
22) Are foreign components allowed at all?
Yes. Foreign components are allowed as defined by the NIH Grants Policy Statement. This means a U.S. applicant organization may include certain foreign elements in the project when justified and structured according to NIH policy, even though a non-U.S. organization cannot be the applicant.
23) What is the overall intent of the program in plain terms?
The program is essentially a bridge from "promising biomarker" to "biomarker that can be used with confidence." It funds the analytical groundwork needed to standardize an assay so that results are reproducible across people and places, with defined reference ranges and quality systems that support use in clinical trials and potentially clinical care.
24) What kinds of biomarker uses are contemplated as examples?
The NOFO provides examples of contexts of use such as patient selection, prognosis, pharmacodynamic response, disease monitoring, or another clearly articulated use case, tied to a specific setting like clinical trial decision-making or routine clinical care.
Browse more opportunities from the same category: Health
Next opportunity: Civil Society Strengthening for Accountability Activity (CSS4A)
Previous opportunity: State Health Insurance Assistance Program (SHIP) Grants
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 25 050
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 25 050) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed) Apply for PA 25 093 Funding Number: PA 25 093 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers on the Demography and Economics of Aging and Alzheimers Disease and Alzheimers Disease-Related Dementias Coordinating Center (U24 Clinical Trial Optional) Apply for RFA AG 25 008 Funding Number: RFA AG 25 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers for Precision Disease Modeling (U54) (Clinical Trials Not Allowed) Apply for PAR 24 305 Funding Number: PAR 24 305 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Systems) (U01 Clinical Trial Not Allowed) Apply for RFA AI 24 067 Funding Number: RFA AI 24 067 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Centers on the Demography and Economics of Aging, Including Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) (D and E Centers) (P30 Clinical Trial Optional) Apply for RFA AG 25 007 Funding Number: RFA AG 25 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Ryan White HIV/AIDS Program Part C Early Intervention Services Program: Limited Existing Geographic Service Areas Apply for HRSA 25 052 Funding Number: HRSA 25 052 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National Rural Health Information Clearinghouse Program Apply for HRSA 25 009 Funding Number: HRSA 25 009 Agency: Health Resources and Services Administration Category: Health Funding Amount: $3,500,000 |
| State Offices of Rural Health Coordination and Development Program (SORHCDP) Apply for HRSA 25 034 Funding Number: HRSA 25 034 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Occupational Safety and Health Education and Research Centers (T42) Apply for RFA OH 25 002 Funding Number: RFA OH 25 002 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $9,000,000 |
| USAID Access Miahy Apply for 72068724RFA00007 Funding Number: 72068724RFA00007 Agency: Madagascar USAID-Antananarivo Category: Health Funding Amount: $90,000,000 |
| Advancing Community Health Activity (ACHA) Apply for 72066924RFA00002 Funding Number: 72066924RFA00002 Agency: Liberia USAID-Monrovia Category: Health Funding Amount: $23,000,000 |
| USAID Access Miahy Apply for 72068724RFA00008 Funding Number: 72068724RFA00008 Agency: Madagascar USAID-Antananarivo Category: Health Funding Amount: $90,000,000 |
| USAID Primary Health Care Improvement Program (UPHIP) Apply for 72062024RFA00009 Funding Number: 72062024RFA00009 Agency: Nigeria USAID-Abuja Category: Health Funding Amount: $40,000,000 |
| Continuation or Revision of NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UH3 Clinical Trial Required) Apply for PAR 25 062 Funding Number: PAR 25 062 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed) Apply for RFA AI 24 068 Funding Number: RFA AI 24 068 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required) Apply for PAR 24 276 Funding Number: PAR 24 276 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Building Biomedical Engineering Education, Research, and Innovation at Historically Black Colleges and Universities (HBCU eBETA) (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA EB 25 002 Funding Number: RFA EB 25 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mental Health and Psychosocial Support (MHPSS) Program in Ethiopia Apply for 72066325RFI00001 Funding Number: 72066325RFI00001 Agency: Ethiopia USAID-Addis Ababa Category: Health Funding Amount: Case Dependent |
| Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21 - Clinical Trial Optional) Apply for PAR 25 115 Funding Number: PAR 25 115 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional) Apply for PAR 25 116 Funding Number: PAR 25 116 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 25 050", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.